• Gustavo Henrique França de Moraes, Luciana Cavalcanti Lima, CouceiroTania Cursino de MenezesTCMDepartment of Anesthesiology, Instituto de Medicina Integral Prof. Fernando Figueira, Recife, Brazil., Mecneide Mendes Lins, CuminoDébora de OliveiraDO0000-0002-6222-1074Department of Pediatric Anesthesiology, Hospital Infantil Sabará, São Paulo, Brazil., Leonardo Augusto Barbosa Magalhães Simões, and MelloMaria Júlia Gonçalves deMJG0000-0003-4645-8343Post Graduate and Research Department, Instituto de Medicina Integral Prof. Fernando Figueira, Recife, Brazil..
• Department of Anesthesiology, Instituto de Medicina Integral Prof. Fernando Figueira, Recife, Brazil.
• Paediatr Anaesth. 2024 Jan 1; 34 (1): 515951-59.

IntroductionDespite preventive strategies, vomiting is an adverse event affecting patients with cancer. However, literature on the incidence and risk factors for vomiting in pediatric patients with cancer are scarce.AimTo assess the incidence and risk factors for vomiting within 24 h and goodness of fit for the Eberhart score in pediatric patients with hematologic cancers after receiving intrathecal chemotherapy under deep sedation.MethodsThis prospective cohort study included patients under 20 years of age with hematologic cancers who were scheduled to undergo intrathecal chemotherapy under anesthesia. The primary outcome was the occurrence of vomiting within 24 h after the end of anesthesia. Sociodemographic and procedure data and underlying diseases were collected. Patients were monitored during the procedure, in the postanesthesia care unit, and the day after (by phone call).ResultsA total of 139 patients were included, and the incidence of vomiting was 30.9% within 24 h after intrathecal chemotherapy under anesthesia, with 90.7% of vomiting prior to 6 h. Prophylactic ondansetron was administered prior to the procedure to 45.3% of patients. Risk factors for vomiting were female gender (hazard ratio: 2.47, 95% confidence interval: 1.35-4.53, p: .003), consolidation phase of treatment (hazard ratio: 2.16, 95% confidence interval: 1.10-4.24, p: .025), and history of kinetosis (hazard ratio: 2.49, 95% confidence interval: 1.31-4.70, p: .005). Incidence of vomit was higher than estimated by the Eberhart score distribution (observed incidence in patients with a score of zero: 33.3%; with a score of one: 28.8%; with a score of two: 60%).ConclusionA high incidence of vomiting was observed within 24 h after intrathecal chemotherapy under propofol deep sedation. Risk factors for this outcome were established (being female, consolidation phase of treatment, and previous kinetosis), and evidence suggested that the Eberhart score was not suitable for the studied population.© 2023 John Wiley & Sons Ltd.

23 keywords...

hide…